- Case report
- Open Access
Major surgery in an osteosarcoma patient refusing blood transfusion: case report
© Dhanoa et al; licensee BioMed Central Ltd. 2010
- Received: 6 July 2010
- Accepted: 8 November 2010
- Published: 8 November 2010
We describe an unusual case of osteosarcoma in a Jehovah's Witness patient who underwent chemotherapy and major surgery without the need for blood transfusion. This 16-year-old girl presented with osteosarcoma of the right proximal tibia requiring proximal tibia resection, followed by endoprosthesis replacement. She was successfully treated with neoadjuvant chemotherapy and surgery with the support of haematinics, granulocyte colony-stimulating factor, recombinant erythropoietin and intraoperative normovolaemic haemodilution. This case illustrates the importance of maintaining effective, open communication and exploring acceptable therapeutic alternative in the management of these patients, whilst still respecting their beliefs.
- Proximal Tibia
- Recombinant Human Erythropoietin
- Minimize Blood Loss
- Recombinant Erythropoietin
Jehovah's Witnesses are well known in the medical world for their refusal on the acceptance of blood and blood products . Unique aspects of these beliefs can pose health care providers with challenging medical, legal and ethical dilemmas. Modifications of standard transfusion practices may be necessary to respect the beliefs of a Jehovah's Witnesses patient and this may be an impediment to optimal care of a patient. We describe here a 16-year-old Jehovah's Witness patient with osteosarcoma who required a major surgery and chemotherapy, which we believe is the first reported such case.
Miss S is a 16-year-old Chinese girl. She presented to a tertiary hospital with an initial complaint of progressively increasing pain and swelling of her right leg of 3 months duration. It was interfering with her right knee movement and walking. It was not associated with any significant trauma and started insidiously. She did not experience any loss of appetite, loss of weight or fever during and around the time of presentation. She had no other known medical conditions prior to this and was not on any medications.
Clinical and radiological findings
Examination of the patient showed a medium built girl with a large swelling measuring 10 cm by 15 cm over her right leg, just below the knee. She did not appear wasted and was walking with an antalgic gait. The skin over the swelling appeared shiny, indurated with visible dilated veins overlying it. Her vital signs were normal and there was no evidence of pallor. On palpation, there was a warm hard swelling arising from the proximal right tibia not crossing the knee joint. It was a smooth lobular swelling, tender on deep palpation. Range of motion for the right knee was 0° to 100° compared to 0° to 140° on the contralateral side. There was no clinical evidence of knee effusion. Examination of all other systems was unremarkable.
During the first encounter with the Orthopaedic Surgeon, the family members confirmed the Jehovah's Witness status of the patient. Subsequently, a meeting between the Orthopaedic Surgeon, the family members and church representatives was held. The Hospital Liaison Committee for Jehovah's Witnesses also sent representatives to provide support to the family and medical literature to the treating doctors for additional information. There was acceptance towards iron and recombinant erythropoietin. However, the family refused packed red blood cells (RBC), whole blood and fresh frozen plasma.
She was started on neoadjuvant chemotherapy which included doxorubicin, cisplatin and high-dose methotrexate with leucovorin (folinic acid) rescue (Memorial Sloan-Kettering protocol). The regime comprised of 6 cycles of chemotherapy. Surgery was performed after 3 cycles of neoadjuvant chemotherapy.
Before commencement of chemotherapy, she was started on ferrous fumarate, folic acid, vitamin B complex and subcutaneous recombinant erythropoietin 50,000 units three times a week. These measures were expected to increase her hemoglobin levels and accelerate red cell production. Immediately after her chemotherapy, she was also given neupogen (granulocyte colony-stimulating factor) to prevent chemotherapy-induced neutropenia. During the course of chemotherapy, her blood counts were stable with the range of recorded hemoglobin of 8.7 to 13.4 g/dL, white blood cell count of 1.9 to 14.8 × 109/L and platelet count of 77 to 268 × 109/L.
Following three cycles of chemotherapy, clinically, there was marked reduction of the tumour mass and patient was prepared for limb salvage surgery. A standard consent for surgery and another one for anaesthesia was obtained from the parents. The parents were clearly informed about the possible risks their child may encounter because of refusal of blood transfusion and this was clearly documented in the medical notes. The patient also had a hand written note describing her religious beliefs and her refusal for blood transfusion, which she showed to all attending doctors. This we believe was because whilst the official medico legal consent form was signed by her parents, she wanted the treating doctors to know that the decision to refuse any form of transfusion was without coercion from external parties.
Three empty blood bags containing anticoagulants routinely used for blood collection were obtained from the blood bank to be used intraoperatively.
Acute normovolaemic haemodilution
Core temperature as measured with an eosophageal probe was allowed to drop to 33.5°C, which is beneficial to reduce basic metabolic rate, hence, the oxygen requirement. Surgery was uneventful and took about 150 minutes to complete. Postoperatively, the limb was bandaged and elevated to minimize blood loss.
The remaining 600 ml of blood was transfused over 6 hours to replace ongoing blood loss as well as to maintain oxygen carrying capacity. Oxygen was administered by face mask at 6 L/min postoperatively. The patient was warmed to normothermia and shivering was prevented. Analgesia was provided by 'patient controlled analgesia' with morphine. All of the above measures reduced oxygen demand and improved oxygen delivery. Her postoperative hemoglobin on the next day was 9.8 g/dL. Meanwhile, the histopathological examination of the resected tumour showed 90% tumour necrosis following neoadjuvant chemotherapy.
Jehovah's Witnesses number 7.3 million in the world . Comparatively, this community is very rare in Malaysia with an estimated number of 3,474 or 0.012% of Malaysian population . Nevertheless, medical practitioners in Malaysia will at some point encounter these patients and should be prepared to manage them under various circumstances. Honoring their beliefs can create challenging therapeutic issues especially when it's not in favor of the principle of beneficence and conflicts with best medical practice.
To the medical fraternity, Jehovah's Witnesses are best known for their prohibition on the acceptance of blood transfusion . The blood ban forbids them from accepting transfusion of allogeneic whole blood and its' components which includes red blood cell (RBCs) concentrates, white blood cells, plasma and platelets [1, 3]. The management of a case such as osteosarcoma includes the use of high dose chemotherapy and surgery, which entails extensive amount of dissection. Blood loss can be significant and this eventually will require the use of blood product supplements.
Variability exists amongst members of Jehovah's Witnesses about opinions on blood ban. Some patients may accept fractions of blood components or recombinant blood products such as granulocyte colony-stimulating factor (G-CSF), recombinant human erythropoietin and clotting fraction concentrates, whilst others will not [1, 4]. Therefore, the patient's preference should be clearly indicated in the medical notes.
During the surgery, normovolaemic haemodilution was utilized, where the autologous blood remains in continuous contact with the patient, with no interruption of the blood circuit [4, 5]. This method ensures hemodynamic stability, while maintaining a continuous circuit between the patient and blood bag . Essentially, the technique of acute normovolaemic haemodilution or intraoperative haemodilution involves withdrawing whole blood from the patient into standard collecting blood bags before or shortly after induction of anaesthesia. Normovolaemia is maintained by replacement with crystalloid or colloid solution. The patient's blood can be reinfused intraoperatively and/or postoperatively as was the case in our patient. Haemodilution is an advantage as any blood lost would contain fewer red blood cells per unit volume  and the circulating blood volume remains constant.
In addition to that, other strategies to conserve blood such as ensuring effective haemostasis to minimize blood loss and the use of tourniquet during surgery were applied. Tourniquets are normally not used during limb salvage surgery as this makes identifying vessels more difficult, but such a practice can lead to more blood loss. Therefore, for this patient a tourniquet was used for the initial phase of superficial and deep dissection, which was subsequently released when it was time to identify and free the neurovascular structures. Meticulous measures were taken to identify and secure haemostasis at the end of surgery.
Chemotherapy was administered based on Memorial Sloan-Kettering protocol and consisted of doxorubicin, cisplatin and high-dose methotrexate. Preoperative chemotherapy allows immediate treatment of micrometastatic disease, aids in limb preservation and enables assessment of chemotherapy response of the tumour. Optimum survival is normally found in patients with good histologic response of the preoperative chemotherapy (more than 90% tumor necrosis) at the time of surgical resection .
During the course of neoadjuvant chemotherapy, the patient's blood counts were monitored both pre and post chemotherapy and haematinics were given from the time of diagnosis to keep her hemoglobin counts high. High-dose recombinant human erythropoietin was also used. It has been shown to significantly increase the haematocrit level with a 50% reduction in the need for blood transfusions  and this is acceptable to many Jehovah's Witnesses. The administration of ferrous fumarate, folic acid, recombinant erythropoietin and G-CSF helped to maintain the hemoglobin and white cell counts during the course of chemotherapy and enhanced the preoperative hemoglobin levels to 13.5 g/dL. These measures are important, as a study conducted among patients who declined blood transfusion for religious reasons has shown that morbidity and mortality rates increased dramatically when the hemoglobin concentration decreased below 6 g/dL . Kitchens  conducted a review of 16 reports of the surgical outcome of a series Jehovah's Witness patients who were not given blood despite undergoing 1,404 surgical procedures that normally would necessitate transfusion. Lack of blood was the primary cause of death in only 0.6% of patients and a contributor to death in another 0.85% of patients.
Fortunately, the platelet count in our patient was stable during the course of chemotherapy and there were no episodes of bleeding. However, if the need arises, recombinant IL-11 (oprelvekin) which is Food and Drug Administration (FDA) approved can be administered . A systematic review examined the appropriate 'trigger' for platelet transfusion after chemotherapy or stem cell transplantation . The authors found no significant differences in mortality, remission rates, severe bleeding events or RBC transfusion requirements between a transfusion threshold of 10 to 20 × 109/L platelets.
Tenenbaum  analyzed the feasibility of oncology treatment in paediatric patients with malignant disease belonging to Jehovah's Witnesses and concluded that such patients can be treated similar to the other patients with a restrictive transfusion policy and broad application of hematopoietic supportive care measures. Also in oncological pediatric patients receiving erythropoietin, a significant reduction in red blood cell and platelet transfusion requirements was shown .
While a competent adult patient has an absolute right to refuse medical treatment, the case of adolescents called mature minors, to decline medical treatment is not as straightforward. In some regions, mature minors are given a right for such consent provided that they are deemed to have sufficient understanding and intelligence to make their own decision . Conversely, in other regions, adolescents depend on parental decision-making or that of the courts, if necessary [4, 15]. Our patient can be considered a mature minor and consent was obtained both from the parents as well as the patient for the decision to decline blood transfusion. These documentation should absolve all doctors and the hospital from any liabilities should the outcome be adverse as a result of transfusion refusal.
This case is like any other case of osteosarcoma of proximal tibia with one major difference. This difference lies not in the biological or science aspect, but social believes which has drastic impact on us, the health care providers. This case illustrates how a major disease which required chemotherapy and surgery was carried out successfully in a Jehovah's Witness patient. Building a good rapport with the patient and maintaining effective, honest communication regarding transfusion options without any element of coercion is the cornerstone in the management of these patients. Rather than discriminating Jehovah's Witness patients because of their beliefs, alternative modern medical care acceptable to these patients can be used to support blood volume and haemostatic function, during the course of treatment of serious diseases.
AD- MBBS, Masters (Path), Consultant Pathologist at Jeffrey Cheah School of Medicine and Health Sciences, Monash University Sunway Campus Malaysia.
VAJ - MBBS, FRCS, Masters (Ortho), Consultant Orthopaedic Oncologist and Associate Professor at Department of Orthopaedic Surgery, University Malaya Medical Centre (UMMC)
RS- MBBS, Masters (Ortho), Orthopaedic Surgeon at Department of Orthopaedic Surgery, UMMC.
RR- MBBS, Masters (Anaes), Consultant Anaesthesiologist at Department of Anaesthesia, UMMC.
Written informed consent was obtained from the patient's parents for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Marsh JC, Bevan DH: Hematological care of the Jehovah's Witness patient. Br J Haematol. 2002, 119: 25-37. 10.1046/j.1365-2141.2002.03639.x.View ArticlePubMedGoogle Scholar
- 2009 Report of Jehovah's Witnesses Worldwide. http://www.watchtower.org/e/statistics/worldwide_report.htm
- Letsoalo JL: Law, blood transfusions and Jehovah's Witnesses. Med Law. 1998, 17: 633-638.PubMedGoogle Scholar
- Hughes DB, Ullery BW, Barie PS: The contemporary approach to the care of Jehovah's Witnesses. J Trauma. 2008, 65: 237-247. 10.1097/TA.0b013e318176cc66.View ArticlePubMedGoogle Scholar
- Benson K: Management of the Jehovah's Witness oncology patient: perspective of the transfusion service. Cancer Control. 1995, 2: 552-556.PubMedGoogle Scholar
- Trouwborst A, Hangenouw RR, Jeekel J, Ong GL: Hypervolaemic haemodilution in an anaemic Jehovah's Witness. Br J Anaesth. 1990, 64: 646-648. 10.1093/bja/64.5.646.View ArticlePubMedGoogle Scholar
- Ta HT, Dass CR, Choong PF, Dunstan DE: Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009, 28: 247-263. 10.1007/s10555-009-9186-7.View ArticlePubMedGoogle Scholar
- Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, Colton T, Corwin MJ: Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial. Crit Care Med. 1999, 27: 2346-2350. 10.1097/00003246-199911000-00004.View ArticlePubMedGoogle Scholar
- Carson JL, Noveck H, Berlin JA, Gould SA: Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion. 2002, 42: 812-818. 10.1046/j.1537-2995.2002.00123.x.View ArticlePubMedGoogle Scholar
- Kitchens CS: Are transfusions overrated? Surgical outcome of Jehovah's Witnesses. Am J Med. 1993, 94: 117-119. 10.1016/0002-9343(93)90171-K.View ArticlePubMedGoogle Scholar
- Du X, Williams DA: Interleukin-11: review of molecular, cell biology, and clinical use. Blood. 1997, 89: 3897-3908.PubMedGoogle Scholar
- Stanworth SJ, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF: Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev. 2004, CD004269-Review, 4Google Scholar
- Tenenbaum T, Hasan C, Kramm CM, Janssen G, Laws HJ, Wessalowski R, Bode U, Göbel U: Oncological management of pediatric cancer patients belonging to Jehovah's Witnesses: A two-institutional experience report. Onkologie. 2004, 27: 131-137. 10.1159/000076901.View ArticlePubMedGoogle Scholar
- Kronberger M, Fischmeister G, Poetschger U, Gadner H, Zoubek A: Reduction in transfusion requirements with early epoietin alfa treatment in pediatric patients with solid tumors: A case-control study. Pediatr Hematol Oncol. 2002, 19: 95-105. 10.1080/08880010252825687.View ArticlePubMedGoogle Scholar
- Woolley S: Jehovah's Witnesses in the emergency department: What are their rights?. Emerg Med J. 2005, 22: 869-871. 10.1136/emj.2004.023382.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.